Information on EC 5.4.99.7 - Lanosterol synthase

New: Word Map on EC 5.4.99.7
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota, Bacteria

EC NUMBER
COMMENTARY
5.4.99.7
-
RECOMMENDED NAME
GeneOntology No.
Lanosterol synthase
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
(3S)-2,3-epoxy-2,3-dihydrosqualene = lanosterol
show the reaction diagram
-
-
-
-
(3S)-2,3-epoxy-2,3-dihydrosqualene = lanosterol
show the reaction diagram
mechanism includes formation of a chair-boat 6-6-5 tricyclic Markovnikov cation and protosteryl cation
-
(3S)-2,3-epoxy-2,3-dihydrosqualene = lanosterol
show the reaction diagram
W232 plays a catalytic role influencing the rearrangement process and determination of deprotonation position but does not interact in the cyclization process
-
(3S)-2,3-epoxy-2,3-dihydrosqualene = lanosterol
show the reaction diagram
catalytic mechanism involving His232 via intermediates parkeol and protosta-12,24-dien-3-beta-ol, quantum mechanics/molecular mechanics, overview
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
cyclization
-
-
-
-
group transfer
-
-
intramolecular
-
isomerization
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Biosynthesis of antibiotics
-
-
Biosynthesis of secondary metabolites
-
-
cholesterol biosynthesis
-
-
lanosterol biosynthesis
-
-
Metabolic pathways
-
-
Steroid biosynthesis
-
-
SYSTEMATIC NAME
IUBMB Comments
(S)-2,3-Epoxysqualene mutase (cyclizing, lanosterol-forming)
-
SYNONYMS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
2,3 oxidosqualene:lanosterol cyclase
-
-
2,3-Epoxysqualene lanosterol-cyclase
-
-
-
-
2,3-epoxysqualene--lanosterol cyclase
-
-
-
-
2,3-Epoxysqualene-lanosterol cyclase
-
-
-
-
2,3-Oxidosqualene cyclase
-
-
-
-
2,3-Oxidosqualene cyclase
-
-
2,3-Oxidosqualene cyclase
-
-
2,3-oxidosqualene cyclase-lanosterol synthase
-
-
2,3-Oxidosqualene sterol cyclase
-
-
-
-
2,3-Oxidosqualene-lanosterol cyclase
-
-
-
-
2,3-oxidosqualene:lanosterol cyclase
-
-
Cyclase, 2,3-oxidosqualene-lanosterol
-
-
-
-
ERG7
Saccharomyces cerevisiae STY2, Saccharomyces cerevisiae TKW14
-
-
-
Erg7p
-
-
Erg7p
Saccharomyces cerevisiae SCY876, Saccharomyces cerevisiae STY2
-
-
-
hOSC
-
-
Lanosterol 2,3-oxidosqualene cyclase
-
-
-
-
lanosterol synthase
-
-
lanosterol synthase
-
-
lanosterol synthase
-
-
lanosterol synthase
-
-
lanosterol synthase
P38604
-
lanosterol synthase
Saccharomyces cerevisiae SMY8
P38604
-
-
LAS
D7NJ68
-
LAS
Ganoderma lucidum HG
D7NJ68
-
-
OSC
-
-
-
-
OSC
-
-
OSC
D7NJ68
-
OSC
Ganoderma lucidum HG
D7NJ68
-
-
OSC
Saccharomyces cerevisiae SCY876 and BTY6-5-3
-
-
-
OSC
Saccharomyces cerevisiae SMY8
P38604
-
-
OSC
Saccharomyces cerevisiae STY2, Saccharomyces cerevisiae TKW14
-
-
-
OSC
-
-
Oxidosqualene cyclase
-
-
-
-
Oxidosqualene cyclase
D7NJ68
-
Oxidosqualene cyclase
Ganoderma lucidum HG
D7NJ68
-
-
Oxidosqualene cyclase
-
-
Oxidosqualene cyclase
-
-
Oxidosqualene cyclase
-
-
Oxidosqualene cyclase
-
-
Oxidosqualene cyclase
P38604
-
Oxidosqualene cyclase
Saccharomyces cerevisiae SCY876 and BTY6-5-3
-
-
-
Oxidosqualene cyclase
Saccharomyces cerevisiae SMY8
P38604
-
-
Oxidosqualene cyclase
Saccharomyces cerevisiae STY2
-
-
-
Oxidosqualene cyclase
-
-
oxidosqualene cyclase/lanosterol synthase
-
-
oxidosqualene cyclase/lanosterol synthase
Saccharomyces cerevisiae SCY876
-
-
-
Oxidosqualene--lanosterol cyclase
-
-
-
-
Oxidosqualene-lanosterol cyclase
-
-
-
-
Oxidosqualene-lanosterol cyclase
-
-
Oxidosqualene-lanosterol cyclase
-
-
Oxidosqualene-lanosterol cyclase
Saccharomyces cerevisiae TKW14
-
-
-
oxidosqualene:lanosterol cyclase
-
-
oxidosqualene:lanosterol cyclase
-
-
oxidosqualene:lanosterol cyclase
-
-
oxidosqualene:lanosterol cyclase
-
-
SceOSC
Saccharomyces cerevisiae SMY8
P38604
-
-
Squalene 2,3-epoxide:lanosterol cyclase
-
-
-
-
Squalene 2,3-oxide-lanosterol cyclase
-
-
-
-
Squalene epoxidase-cyclase
-
-
-
-
Squalene-2,3-oxide-lanosterol cyclase
-
-
-
-
CAS REGISTRY NUMBER
COMMENTARY
9032-71-7
-
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
coexistence of cycloartenol synthase and lanosterol synthase
-
-
Manually annotated by BRENDA team
Ganoderma lucidum HG
-
UniProt
Manually annotated by BRENDA team
recombinant enzyme
-
-
Manually annotated by BRENDA team
Cynomolgus
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
Shumiya cataract rat
Uniprot
Manually annotated by BRENDA team
strain SCY876
-
-
Manually annotated by BRENDA team
strain SMY8
SwissProt
Manually annotated by BRENDA team
strain TKW14
-
-
Manually annotated by BRENDA team
Saccharomyces cerevisiae SCY876
strain SCY876
-
-
Manually annotated by BRENDA team
Saccharomyces cerevisiae SCY876 and BTY6-5-3
-
-
-
Manually annotated by BRENDA team
Saccharomyces cerevisiae SMY8
strain SMY8
SwissProt
Manually annotated by BRENDA team
Saccharomyces cerevisiae STY2
strain STY2
-
-
Manually annotated by BRENDA team
Saccharomyces cerevisiae TKW14
strain TKW14
-
-
Manually annotated by BRENDA team
Gttingen minipig
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
metabolism
-
part of cholesterol synthesis pathway
physiological function
-
functional role of the Cys703 residue in stabilizing the bicyclic C-8 cation and the rearranged intermediate or interacting with Phe699
metabolism
-
oxidosqualene-lanosterol cyclase is a key enzyme in the biosynthesis of cholesterol
additional information
-
H232 mutant energy profiles compared to the wild-type enzyme, overview
additional information
-
structure-function-mechanism relationships, overview
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(3R)-Squalene epoxide
Epilanosterol
show the reaction diagram
-
-
-
-
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol
show the reaction diagram
-
reaction of wild-type enzyme
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol
show the reaction diagram
-
reaction of wild-type enzyme, via intermediates parkeol and protosta-12,24-dien-3-beta-ol
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol
show the reaction diagram
-
the enzyme performs the polycyclization reaction by folding the substrate in a chair-boat-chair-chair conformation
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
achilleol A
show the reaction diagram
-
reaction of mutant H234W/Y510W
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
achilleol A
show the reaction diagram
-
reaction of mutant Q450H
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol + (13alphaH)-isomalabarica-14(26),17E,21-trien-3beta-ol
show the reaction diagram
-
reaction of mutant V454I
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol + (13alphaH)-isomalabarica-14(26),17E,21-trien-3beta-ol + protosta-16,24-dien-3beta-ol
show the reaction diagram
-
reaction of mutant Q450H/V454I
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol + achilleol A
show the reaction diagram
-
reaction of C457G/T509G
achilleol A is the main product
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol + achilleol A + 13alphaH-isomalabarica-14(26),17E,21-trien-3beta-ol
show the reaction diagram
-
reaction of mutant H234W/Y510V
lanosterol is the main product
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol + parkeol + 9beta-lanosta-7,24-dien-3beta-ol
show the reaction diagram
-
reaction of mutants T384Y, T384Y/Q450H, and T384Y/V454I
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
parkeol
show the reaction diagram
-
reaction of mutant H232S
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
parkeol
show the reaction diagram
-
reaction of mutant T384Y/Q450H/V454I
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
protosta-12,24-dien-3-beta-ol
show the reaction diagram
-
reaction of mutant H232T
-
-
?
(3S)-2,3-oxidosqualene
?
show the reaction diagram
-
two essential histidine residues per active site are necessary for complete activity
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
P38604
-
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
Q603D4
reaction is completely regio- and stereospecific
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
Saccharomyces cerevisiae SMY8
P38604
-
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
Saccharomyces cerevisiae TKW14
-
-
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
Saccharomyces cerevisiae STY2
-
-
-
-
?
(3S)-Squalene epoxide
?
show the reaction diagram
-
-
-
-
-
(3S)-Squalene epoxide
?
show the reaction diagram
-
-
-
-
-
(3S)-squalene-2,3-epoxide
lanosterol
show the reaction diagram
-
-
-
-
?
(S)-2,3-epoxysqualene
lanosterol
show the reaction diagram
-
-
-
?
(S)-2,3-epoxysqualene
lanosterol
show the reaction diagram
P48450
-
-
-
?
(S)-2,3-epoxysqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(S)-2,3-epoxysqualene
lanosterol
show the reaction diagram
-
-
lanosterol is the only product in wild-type
-
-
(S)-2,3-epoxysqualene
lanosterol
show the reaction diagram
-
-
no other product observed
-
?
(S)-2,3-epoxysqualene
lanosterol
show the reaction diagram
-
-
synthesis of about 0.1% parkeol as byproduct
-
-
(S)-2,3-epoxysqualene
lanosterol
show the reaction diagram
-
formation of lanosterol the first sterol precursor of cholesterol in mammals
-
?
(S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
Saccharomyces cerevisiae SCY876
-
-
-
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
D7NJ68
-
-
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
Saccharomyces cerevisiae SCY876 and BTY6-5-3
-
-
-
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
Ganoderma lucidum HG
D7NJ68
-
-
-
?
2,3-monoepoxysqualene
lanosterol
show the reaction diagram
-
-
-
-
?
2,3-monoepoxysqualene
lanosterol
show the reaction diagram
-
-
-
-
?
2,3-monoepoxysqualene
lanosterol
show the reaction diagram
-
-
-
-
?
2,3-monoepoxysqualene
lanosterol
show the reaction diagram
-
-
-
-
?
2,3-oxidosqualene
lanosterol
show the reaction diagram
P48449
-
-
-
?
2,3-oxidosqualene
lanosterol
show the reaction diagram
P48450
-
-
-
?
2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
2,3:22,23-diepoxysqualene
24(S),25-epoxylanosterol
show the reaction diagram
-
-
-
-
?
2,3:22,23-diepoxysqualene
24(S),25-epoxylanosterol
show the reaction diagram
-
-
-
-
?
2,3:22,23-diepoxysqualene
24(S),25-epoxylanosterol
show the reaction diagram
-
-
-
-
?
2,3:22,23-diepoxysqualene
24(S),25-epoxylanosterol
show the reaction diagram
-
-
-
-
?
2,3:22,23-diepoxysqualene
24(S),25-epoxylanosterol
show the reaction diagram
-
-
-
-
?
2,3:22,23-diepoxysqualene
24(S),25-epoxylanosterol
show the reaction diagram
-
this reaction is enhanced when OSC is inhibited
-
-
?
27-norsqualene
30-norlanosterol + 26-normalabaricatriene
show the reaction diagram
-
-
-
-
?
29-norsqualene
(2S,4aS,6aR,7R,10aR,12aR)-1,1,4a,6a,10a-pentamethyl-7-(4-methylpent-3-en-1-yl)-1,2,3,4,4a,5,6,6a,7,8,9,10,10a,11,12,12a-hexadecahydrochrysen-2-ol + (2S,4aS,6aS,7R,10aS,12aR)-1,1,4a,6a,10a-pentamethyl-7-(4-methylpent-3-en-1-yl)-1,2,3,4,4a,5,6,6a,7,8,9,10,10a,11,12,12a-hexadecahydrochrysen-2-ol
show the reaction diagram
-
-
-
-
?
3-[(3E,7E,15E)-16-ethyl-3,7,12,20-tetramethylhenicosa-3,7,11,15,19-pentaen-1-yl]-2,2-dimethyloxirane
?
show the reaction diagram
-
ethylation at C10 or C15
-
-
?
oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
squalene
?
show the reaction diagram
Saccharomyces cerevisiae, Saccharomyces cerevisiae SMY8
P38604
-
-
-
?
dioxidosqualene
24(S),25-epoxylanosterol
show the reaction diagram
Saccharomyces cerevisiae, Saccharomyces cerevisiae STY2
-
-
-
-
?
additional information
?
-
Q964Q1
trypanosome and animal lanosterol synthases use different catalytic motifs
-
?
additional information
?
-
-
central role in sterol biosynthesis
-
-
-
additional information
?
-
-
central role in sterol biosynthesis
-
-
-
additional information
?
-
-
mutant enzyme display altered product profiles compared to the wild-type enzyme producing also e.g. achilleol A, camelliol C, 13alphaH-isomalabarica-14(26),17E,21-trien-3beta-ol, protosta-12(13),24-dien-3beta-ol, protosta-13(17),24-dien-3beta-ol, or parkeol, overview
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-epoxy-2,3-dihydrosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(3S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
Saccharomyces cerevisiae, Saccharomyces cerevisiae SMY8
P38604
-
-
-
?
(S)-2,3-epoxysqualene
lanosterol
show the reaction diagram
P48450
-
-
-
?
(S)-2,3-epoxysqualene
lanosterol
show the reaction diagram
-
formation of lanosterol the first sterol precursor of cholesterol in mammals
-
?
(S)-2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
-
-
-
-
?
(S)-squalene-2,3-epoxide
Lanosterol
show the reaction diagram
Saccharomyces cerevisiae SCY876 and BTY6-5-3
-
-
-
-
?
2,3-monoepoxysqualene
lanosterol
show the reaction diagram
-
-
-
-
?
2,3-monoepoxysqualene
lanosterol
show the reaction diagram
-
-
-
-
?
2,3-monoepoxysqualene
lanosterol
show the reaction diagram
-
-
-
-
?
2,3-monoepoxysqualene
lanosterol
show the reaction diagram
-
-
-
-
?
2,3-oxidosqualene
lanosterol
show the reaction diagram
P48449
-
-
-
?
2,3-oxidosqualene
lanosterol
show the reaction diagram
-
-
-
-
?
additional information
?
-
-
central role in sterol biosynthesis
-
-
-
additional information
?
-
-
central role in sterol biosynthesis
-
-
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
potassium phosphate
-
high concentrations stimulate
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
-
IC50: 0.0015 mM
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
-
IC50: 0.0004 mM
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.0015 mM, irreversible; potent, irreversible
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.0035 mM, irreversible; potent, irreversible
(18E)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0015 mM
(18E)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0035 mM
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.03 mM
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.05 mM
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.015 mM; potent, irreversible
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.02 mM; potent, irreversible
(18Z)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.001 mM
(18Z)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0004 mM
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.05 mM
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.06 mM
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
-
IC50: 0.05 mM
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
-
IC50: 0.1 mM
(22E)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
(22Z)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Pneumocystis carini, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
comparison with inhibitory effect on Pneumocystis carinii, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Pneumocystis carini, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
comparison with inhibitory effect on Pneumocystis carinii, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and Pneumocystis carinii enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Saccharomyces cerevisiae, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Trypanosoma cruzi, Pneumocystis carini, and human enzyme
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
comparison with inhibitory effect on Pneumocystis carinii, Saccharomyces cerevisiae, and human enzyme
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
-
IC50: 0.0015 mM
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
-
IC50: 0.0025 mM
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
-
IC50: 0.025 mM
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
-
IC50: 0.012 mM
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
-
IC50: 0.04 mM
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
-
IC50: 0.0075 mM
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
-
IC50: 0.0025 mM
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
-
IC50: 0.001 mM
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 143 nM
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 326 nM
(4-bromophenyl)[4-[6-(cyclopropylmethylmethylamino)hexyloxy]phenyl]methanone
-
IC50: 31.8 nM
(4-bromophenyl)[4-[6-[(3-hydroxypropyl)methylamino]-hexyloxy]phenyl]methanone
-
IC50: 15.7 nM
(4aalpha,5alpha,6alpha,8abeta)-Decahydro-5,8a-dimethyl-2-(1,5,9-trimethyldecyl)-6-isoquinolinol
-
and simplified analogues
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
-
IC50: 0.0015 mM
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
-
IC50: 0.005 mM
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
-
IC50: 0.00005 mM
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
-
IC50: 0.001 mM
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene, IC50: 0.06 mM
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
-
IC50: 0.018 mM
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
-
IC50: 0.032 mM
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.05 mM
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.02 mM
(5Z,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene, IC50: 0.06 mM
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.05 mM
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.02 mM
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
-
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.003 mM, at a protein concentration of 3 mg/ml
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.0048 mM, at a protein concentration of 5 mg/ml
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.005 mM, at a protein concentration of 2 mg/ml
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.005 mM, at a protein concentration of 1 mg/ml
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.005 mM
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.004 mM
(6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
(6Z)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
poor
(6Z)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.1 mM, at a protein concentration of 3 mg/ml
(6Z)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.02 mM, at a protein concentration of 5 mg/ml
(6Z)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.1 mM, at a protein concentration of 2 mg/ml
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
-
IC50: 0.012 mM
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
-
IC50: 0.0022 mM
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.001 mM
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.0004 mM
(6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
-
IC50: 83 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
-
IC50: 124 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
1,2-dilinoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
26% inhibition at 0.5 microM, no inhibition at 0.25 microM
1,2-dimyristoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
72% inhibition at 0.5 microM, 51% at 0.25 microM
1,2-dioleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
57% inhibition at 0.5 microM, 42% at 0.25 microM
1,2-dipalmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
24% inhibition at 0.5 microM, 4% at 0.25 microM
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
IC50: 112 nM
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
76% inhibition at 0.001 mM, IC50: 398 nM
1-(2-oxazolinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
87% inhibition at 0.001 mM
1-(2-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
8% inhibition at 0.001 mM
1-(2-thiazolinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
complete inhibition at 0.001 mM
1-(4-iodophenylsulfonyl)-4-(1-(4-pyridyl)piperidon-4-ylcarbonyl)piperazine
-
IC50: 82 nM
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
IC50: 37 nM
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
complete inhibition at 0.001 mM, IC50: 116 nM
1-linolenoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
26% inhibition at 0.5 microM, 5% inhibition at 0.25 microM
1-linoleoyl-2-linolenoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
45% inhibition at 0.5 microM, 18% at 0.25 microM
1-linoleoyl-2-myristoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
38% inhibition at 0.5 microM, 22% at 0.25 microM
1-linoleoyl-2-oleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
31% inhibition at 0.5 microM, 8% at 0.25 microM
1-linoleoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
27% inhibition at 0.5 microM, 3% at 0.25 microM
1-myristoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
45% inhibition at 0.5 microM, 35% at 0.25 microM
1-oleoyl-2-linolenoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
29% inhibition at 0.5 microM, 7% at 0.25 microM
1-oleoyl-2-linoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
40% inhibition at 0.5 microM, 9% at 0.25 microM
1-oleoyl-2-palmitoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
46% inhibition at 0.5 microM, 24% at 0.25 microM
1-palmitoyl-2-linoleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
20% inhibition at 0.5 microM, no inhibition at 0.25 microM
1-palmitoyl-2-oleoyl-3-(alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl)-sn-glycerol
-
21% inhibition at 0.5 microM, 4% at 0.25 microM
1-[4-(trifluoromethoxy)phenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmeth yl]-piperazine
-
-
1-[4-chlorobenzyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(1-methyl-pyrazol-4-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-1-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-3-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
1-[4-chlorophenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[3-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(4-methylpiperazin-1-yl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
-
-
1-[4-chlorophenylsulfonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-methoxyphenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
1-[4-trifluoroacetyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
-
inactive at 200 nM
10,15-desdimethyl-2,3-oxidosqualene
-
-
10-desmethyl-2,3-oxidosqualene
-
-
18,19-dihydro-29-methylidene-2,3-oxidosqualene
-
IC50: 0.1 mM
18-heptanor-2,3-oxidosqualene
-
IC50: 0.07 mM
18-heptanor-2,3-oxidosqualene
-
IC50: 0.015 mM
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.022 mM, protein concentration of 3 mg/ml
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.0075 mM, protein concentration of 5 mg/ml
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.035 mM, at a protein concentration of 2 mg/ml
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.0015 mM
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide
-
noncompetitive
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
-
-
19-Aza-18,19,22,3-tetrahydrosqualene-2,3-epoxide N-oxide
-
poor, competitive
2,3,18,19-Dioxidosqualene stereoisomers
-
-
2,3-Epoxy-10-aza-10,11-dehydrosqualene
-
6E isomer strongly inhibits enzyme in both cell cultures and microsomes; weak inhibition by 6Z isomer
2,3-Epoxy-10-aza-10,11-dehydrosqualene
-
6E isomer strongly inhibits enzyme in both cell cultures and microsomes; 6Z isomer has no effect on microsomal enzyme
2,3-Iminosqualenene
-
-
-
2-Aza-2,3-dihydrosqualene
-
-
2-Aza-2,3-dihydrosqualene
-
0.01 mM, 70% inhibition; IC50: 6.5 mM
2-Aza-2,3-dihydrosqualene
-
0.01 mM, 70% inhibition; IC50: 7.5 mM
2-Aza-2,3-dihydrosqualene
-
0.01 mM, 70% inhibition; IC50: 10 mM
2-Aza-2,3-dihydrosqualene
-
IC50: 2.3 mM, pig microsomes. IC50: 0.15 mM, solubilized enzyme
2-Aza-2,3-dihydrosqualene alcohol
-
-
-
2-Aza-2,3-dihydrosqualene N-oxide
-
-
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 3.7 mM
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 16 mM
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 7 mM, pig microsomes. IC50: 3.3 mM, solubilized enzyme
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
-
IC50: 0.0025 mM
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
-
IC50: 0.006 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
-
IC50: 0.0035 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
-
IC50: 0.012 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
-
IC50: 0.00017 mM
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
-
IC50: 0.00035 mM
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
-
IC50: 0.035 mM
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
-
IC50: 0.1 mM
22,23-Epoxy-2-aza-2,3-dihydrosqualene
-
slight
22,23-epoxy-2-aza-2,3-dihydrosqualene-N-oxide
-
0.01 mM, 14% inhibition
27,28-bisnoroxidosqualene
-
irreversible inhibition
-
27-norsqualene
-
-
28-noroxidosqualene
-
-
-
29-Methylidene-2,3-oxidohexanorsqualene
-
-
-
29-norsqualene
-
-
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
-
IC50: 0.0015 mM
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
-
IC50: 0.0035 mM
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 0.016 mM
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 280 nM
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 750 nM
3-beta-(beta-dimethylaminoethoxy)-androst-5en-17one
-
DMAE-DHA
3-carboxy-4-nitrophenyldithio-1,1',2-tris-nor-squalene
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidin-3-ol
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
-
-
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
-
IC50: 160 nM
3-[2-(4-bromobenzophenone)ethynyl]quinuclidin-3-ol
-
-
3-[Methyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-amino]-propan-1-ol
-
0.01 mM, 2% inhibition
3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride
-
U18666A
4,4,10beta-trimethyl-trans-decal-3beta-ol
-
specific inhibitor
4-(4-bromobenzoyl)-1-(1-(4-pyridyl)piperidin-4-ylcarbonyl)piperazine
-
96% inhibition at 0.001 mM
4-(4-bromophenylmethyl)-1-(1-(4-pyridyl)piperidin-4-ylcarbonyl)piperazine
-
complete inhibition at 0.001 mM
4-chloro-N-(4-{4-[(dimethylamino)methyl]phenyl}cyclohexyl)-N-methylbenzamide
-
BIBX 79
6-desmethyl-2,3-oxidosqualene
-
-
7-(4'-allylmethylamino-but-2-ynyloxy)chromen-2-one
-
-
-
7-(morpholinyl-N-hexyloxy)chromen-2-one
-
-
-
7-(morpholinyl-N-octanyloxy)chromen-2-one
-
-
-
7-(piperidinyl-N-hexyloxy)chromen-2-one
-
-
-
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
-
-
-
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
-
-
-
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
-
-
-
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
-
-
-
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
-
-
-
allyl-6-[4-(4-bromophenyl)-1H-benzo[d][1,2]oxazin-7-yloxy]hexylmethylamine
-
IC50: 4.1 nM
allyl[6-[1-(4-bromophenyl)-3,4-dihydroisoquinolin-6-yloxy]hexyl]methylamine
-
IC50: 7.9 nM
allyl[6-[1-(4-bromophenyl)isoquinolin-6-yloxy]hexyl]methylamine
-
IC50: 3.5 nM
allyl[6-[3-(4-bromophenyl)-1-methyl-1H-indazol-6-yloxy]hexyl]methylamine
-
IC50: 19.6 nM
allyl[6-[3-(4-bromophenyl)benzo[b]thiophen-6-yloxy]hexyl]methylamine
-
IC50: 5.6 nM
allyl[6-[3-(4-bromophenyl)benzo[d]isothiazol-6-yloxy]hexyl]methylamine
-
IC50: 2.9 nM
allyl[6-[4-(4-bromophenyl)-2H-chromen-7-yloxy]hexyl]methylamine
-
IC50: 11.4 nM
allyl[6-[4-(4-bromophenyl)quinazolin-7-yloxy]hexyl]methylamine
-
IC50: 12.3 nM
allyl[6-[4-(6-bromo-1,1-dioxobenzo[d]isothiazol-3-yl)phenoxy]hexyl]methylamine
-
IC50: 7.8 nM
azasqualene alcohol
-
0.01 mM, 13% inhibition
azasqualene alcohol N-oxide
-
IC50: 0.055 mM, at a protein concentration of 3 mg/ml
azasqualene alcohol N-oxide
-
IC50: 0.055 mM, at a protein concentration of 2 mg/ml
BIBB 515
-
-
-
Chloroquine
-
-
cholesterol
-
an increased cholesterol level suppresses the expression of 2,3-oxidosqualene cyclase
dehydrocostus lactone
-
isolated from Laurus nobilis extract, 22% inhibition at 0.25 mM, 63% inhibition at 0.5 mM
diethyl dicarbonate
-
maximal inactivation at neutral pH, reactivation by hydroxylamine
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
-
IC50: 1.5 mM
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
-
IC50: 14 mM
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 3.2 mM
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 12.5 mM
dodecyl-maleimide
P38604
mutant C457D shows 41.6% inhibition at 1 mM, 10.0% at 0.2 mM, and 7.2% at 0.025 mM, mutant C457D/E526A shows 9.0% inhibition at 0.2 mM and 0.0% at 0.025 mM, mutant C457D/A525C shows 86.0% inhibition at 1 mM, 30.5% at 0.2 mM, and 1.0% at 0.025 mM, mutant C457D/E526C shows 89.6% inhibition at 0.2 mM, 74.7% at 0.025 mM, and 45.1% at 0.01 mM
-
eremanthine
-
isolated from Laurus nobilis extract, 12% inhibition at 0.25 mM, 70% inhibition at 0.5 mM
ethanol extract from Angelica keiskei leaves
-
11% inhibition at 0.3 mg/ml
-
ethanol extract from Basella rubra leaves
-
5% inhibition at 0.3 mg/ml
-
ethanol extract from Chrysanthemum morifolium flowers
-
13% inhibition at 0.3 mg/ml
-
ethanol extract from Chrysanthemum morifolium leaves
-
7% inhibition at 0.3 mg/ml
-
ethanol extract from Colocasia esculenta rhizomes
-
55% inhibition at 0.3 mg/ml
-
ethanol extract from Cryptotaenia japonica leaves
-
10% inhibition at 0.3 mg/ml
-
ethanol extract from Glycine max immature seeds
-
14% inhibition at 0.3 mg/ml
-
ethanol extract from Oenanthe stolonifera leaves
-
13% inhibition at 0.3 mg/ml
-
ethanol extract from Perilla frutescens leaves
-
5% inhibition at 0.3 mg/ml
-
ethanol extract from Petasites japonicus buds
-
6% inhibition at 0.3 mg/ml
-
ethanol extract from Zingiber officinale buds
-
14% inhibition at 0.3 mg/ml
-
ethanol extract from Zingiber officinale rhizomes
-
6% inhibition at 0.3 mg/ml
-
KCl
-
at high concentrations
N,N-Diethylazasqualene
-
non-competitive
N,N-Diethylazasqualene N-oxide
-
competitive
N,N-dimethyl-N-(4-methylenebenzophenonyl)amine
-
IC50: 0.005 mM
N,N-Dimethylformamide
P38604
-
N-(1-Oxododecyl)-4alpha,10-dimethyl-8-aza-trans-decal-3beta-ol
-
potent, competitive
N-(2-methylenebenzophenonyl)pyridinium
-
IC50: 0.059 mM
N-(3-methylenebenzophenonyl)pyridinium bromide
-
IC50: 0.016 mM
N-(4-methylenebenzophenonyl)pyridinium bromide
-
IC50: 0.00079 mM
N-(Ethoxycarbonyl)-2-ethoxy-1,2-dihydroquinoline
-
slight
N-[(1,5,9)-Trimethyl-decyl]-4alpha,10-dimethyl-8-aza-decal-3beta-ol
-
strong
N-[2-(4-(3-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
-
inactive at 200 nM
N-[2-(4-(4-((pyrrolidin-1-yl)methyl)phenyl)phenyl)ethyl]-4-chlorobenzenesulfonamide
-
-
N-[2-(4-(4-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
-
-
N-[3-(1,1'-biphenyl-4-yloxy)propyl]-N,N-dimethylamine
-
IC50: 2500 nM
NaCl
-
at high concentrations
NEM
-
1 mM, 20% inhibition
NEM
-
following pseudo-first order kinetics
Ro 48-8071
-
IC50: 8.0 nM for the recombinant enzyme, IC50: 6.5 nM for the human liver enzyme
Ro 48-8071
P48449
-
RO0717625
-
-
-
Ro48-8071
-
IC50: 22 nM
Ro48-8071
-
-
Squalene maleimide
-
-
-
Sulfur-substituted squalene oxide analogues
-
mechanism-based inhibition
-
trans-N-(4-(5-[ethyl-(2-hydroxy-ethyl)-amino]-pentyl)-cyclohexyl)-N-methyl-4-trifluoromethyl-benzenesulfonamide fumarate
-
RO0714565
-
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 13.3 mM
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 5.1 mM
U18666A
-
-
U18666A
-
produce cataract formation
ZD-9720
-
-
[19-(3,3-Dimethyl-oxiranyl)-4,8,13,17-tetramethyl-nonadeca-4,8,12,16-tetraenyl]-dimethyl-amine
-
0.01 mM, 8% inhibition
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromo-phenyl)-methanone fumarate
-
RO0488071
[4'-(6-allyl-methyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromophenyl)-methanone fumarate
-
Ro 48-8071
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 92 nM
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 22 nM
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 400 nM
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 161 nM
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 228 nM
[4-[6-(allylmethylamino)hexyloxy]-2-hydroxyphenyl](4-bromophenyl)methanone
-
IC50: 6.3 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methoxyphenyl](4-bromophenyl)methanone
-
IC50: 4.6 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methylaminophenyl](4-bromophenyl)methanone
-
IC50: 4.1 nM
[4-[6-(allylmethylamino)hexyloxy]-2-methylsulfanylphenyl](4-bromophenyl)methanone
-
IC50: 6.2 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-bromophenol)methanone
-
IC50: 5.4 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-nitrophenyl)methanone
-
IC50: 1.9 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl]-(4-fluorophenyl)methanone
-
IC50: 6.7 nM
[4-[6-(allylmethylamino)hexyloxy]phenyl]phenylmethanone
-
IC50: 22.5 nM
[5-(4-(4-chloro-benzoyl)-3-fluoro-phenoxy)-pentyl]-methyl-propyl-ammonium fumarate
-
IC50: 49 nM
[6-[6-(allylmethylamino)hexyloxy]pyridin-3-yl](4-bromophenyl)methanone
-
IC50: 8.7 nM
[6-[6-(cyclopropylmethylamino)hexyloxy]phenyl](4-bromophenyl)methanone
-
IC50: 35.3 nM
{4-[4-(4,5-Dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-(4-trifluoromethyl-phenyl)-methanone
-
IC50: 90 nM, complete inhibition at 0.001 nM
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 4.6 nM
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 4.3 nM
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 71 nM
KCl
-
0-0.1 M: activity decreases with increasing concentration of KCl in the presence of optimal concentrations of Triton X-100
additional information
-
in solutions of low ionic strength the enzyme polymerizes to an inactive form
-
additional information
-
no inhibition: EDTA, diethyldicarbonate, phenylmethylsulfonyl fluoride
-
additional information
-
antifungal activity of lanosterol synthase inhibitors
-
additional information
-
-
-
additional information
-
no inhibition: cholesterol
-
additional information
-
oxidosqualene cyclase inhibitors as antimicrobial agents
-
additional information
-
3-alpha-D-galactopyranosyl-1,6-beta-D-galactopyranosyl-sn-glycerol has no inhibitory effect
-
additional information
-
a high fat diet reduces OSC expression in the liver
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
deoxycholate
-
the effective concentration range for enzyme activation is extremely narrow, around 0.1%. The enzyme activity may depend not only on the final concentration of sodium deoxycholate but also on its ratio to protein
Erg27p
-
required for activity of Erg7p
-
Rat liver cytosol carrier protein
-
enhances lanosterol synthase activity in placental microsomes
S105 protein from rat liver
-
required for optimal activity. The S105 protein acts internally within the microsomal membrane system facilitating the access of substrate to specific enzyme sites
-
steroid-3-ketoreductase
-
-
-
Triton X-100
-
concentration range for optimal activity: 0.7-1.2%
Triton X-100
-
0.05-0.15%, activates solubilized enzyme up to 300%
jasmonate
-
LAS1 gene expression is induced by the application of jasmonate
additional information
-
no protective action of steroid-3-ketoreductase towards OSC is necessary
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.075
(3S)-2,3-epoxy-2,3-dihydrosqualene
-
pH 7.4, 37C, liver microsomes
0.011
(3S)-2,3-oxidosqualene
-
-
0.055
(3S)-squalene epoxide
-
-
0.015
2,3-epoxysqualene
-
-
0.025
2,3-epoxysqualene
-
-
0.035
2,3-epoxysqualene
-
-
0.231
3-[(3E,7E,15E)-16-ethyl-3,7,12,20-tetramethylhenicosa-3,7,11,15,19-pentaen-1-yl]-2,2-dimethyloxirane
-
pH 7.4, 37C, liver microsomes
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.000013
27-norsqualene
-
pH 7.4, 37C, liver microsomes
0.00002
28-noroxidosqualene
-
pH 7.4, 37C, liver microsomes
-
0.00112
7-(4'-allylmethylamino-but-2-ynyloxy)chromen-2-one
-
-
-
0.00342
7-(4'-allylmethylamino-but-2-ynyloxy)chromen-2-one
-
-
-
0.07876
7-(morpholinyl-N-hexyloxy)chromen-2-one
-
-
-
0.09583
7-(morpholinyl-N-hexyloxy)chromen-2-one
-
-
-
0.1028
7-(morpholinyl-N-hexyloxy)chromen-2-one
-
-
-
0.00535
7-(morpholinyl-N-octanyloxy)chromen-2-one
-
-
-
0.03067
7-(morpholinyl-N-octanyloxy)chromen-2-one
-
-
-
0.00248
7-(piperidinyl-N-hexyloxy)chromen-2-one
-
-
-
0.03154
7-(piperidinyl-N-hexyloxy)chromen-2-one
-
-
-
0.00018
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
-
-
-
0.00321
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
-
-
-
0.00414
7-[10-(allylmethylamino)-decyloxy]chromen-2-one
-
-
-
0.00185
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
-
-
-
0.02035
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
-
-
-
0.07266
7-[4'-(N-diethylamino)-but-2-ynyloxy]chromen-2-one
-
-
-
0.00052
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
-
-
-
0.01028
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
-
-
-
0.1063
7-[4'-(N-pyrrolidyn)-but-2-ynyloxy]chromen-2-one
-
-
-
0.00015
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
-
-
-
0.00104
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
-
-
-
0.00406
7-[6-(allylmethylamino)-hexyloxy]-chromen-2-one
-
-
-
0.00104
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
-
-
-
0.00603
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
-
-
-
0.02543
7-[8'(dimethylamino-N-octyloxy)]chromen-2-one
-
-
-
0.008
S23515
-
-
-
0.000015
29-norsqualene
-
pH 7.4, 37C, liver microsomes
additional information
7-(4'-allylmethylamino-but-2-ynyloxy)chromen-2-one
-
above 0.1 mM
-
0.1024
7-(morpholinyl-N-octanyloxy)chromen-2-one
-
-
-
additional information
7-(piperidinyl-N-hexyloxy)chromen-2-one
-
above 0.1 mM
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0004
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
-
IC50: 0.0004 mM
0.0015
(14-trans)-28-methylidene-2,3:14,15-dioxidoundecanorsqualene
-
IC50: 0.0015 mM
0.0015
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.0015 mM, irreversible
0.0035
(18E)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.0035 mM, irreversible
0.0015
(18E)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0015 mM
0.0035
(18E)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0035 mM
0.03
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.03 mM
0.05
(18E)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.05 mM
0.015
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.015 mM
0.02
(18Z)-29-Methylidene-2,3-oxidohexanorsqualene
-
IC50: 0.02 mM
0.0004
(18Z)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.0004 mM
0.001
(18Z)-29-methylidene-2,3-oxidosqualene
-
IC50: 0.001 mM
0.05
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.05 mM
0.06
(18Z)-29-methylidene-20,21,22,23,24,30-hexanor-2,3-oxidosqualene
-
IC50: 0.06 mM
0.05
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
-
IC50: 0.05 mM
0.1
(2-trans)-1-methylidene-2,3-oxido-1'-norsqualene
-
IC50: 0.1 mM
0.1
(22E)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
0.1
(22Z)-24-methylidene-30-nor-2,3-oxidosqualene
-
IC50: above 0.1 mM
0.0017
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
-
0.0045
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
-
0.0074
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-biphenyl-4-ylpropyl ether
-
-
0.00033
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
-
0.00045
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
-
0.00047
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
-
0.0011
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl 3-phenylpropyl ether
-
-
0.00036
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
-
0.00085
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
-
0.00178
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
-
0.0027
(2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6-decadien-1-yl hexyl ether
-
-
0.0015
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
-
IC50: 0.0015 mM
0.0025
(3-trans-7E,11E,15E)-3,4:19,20-diepoxy-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraene
-
IC50: 0.0025 mM
0.012
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
-
IC50: 0.012 mM
0.025
(3R,4S,7E)-15,16-epoxy-3-ethylthio-8,12,16-trimethyl-1,7,11-heptadecatrien-4-ol
-
IC50: 0.025 mM
0.0075
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
-
IC50: 0.0075 mM
0.04
(3R,4S,7E,11E)-15,16-epoxy-8,12,16-trimethyl-3-phenylthio-1,7,11-heptadecatrien-4-ol
-
IC50: 0.04 mM
0.001
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
-
IC50: 0.001 mM
0.0025
(3R,4S,7E,11E,15E)-19,20-epoxy-3-ethylthio-7,12,16,20-tetramethyl-1,7,11,15-henicosatetraen-4-ol
-
IC50: 0.0025 mM
0.000143
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 143 nM
0.000326
(4-Benzenesulfonyl-piperazin-1-yl)-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 326 nM
0.0000318
(4-bromophenyl)[4-[6-(cyclopropylmethylmethylamino)hexyloxy]phenyl]methanone
-
IC50: 31.8 nM
0.0000157
(4-bromophenyl)[4-[6-[(3-hydroxypropyl)methylamino]-hexyloxy]phenyl]methanone
-
IC50: 15.7 nM
0.0015
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
-
IC50: 0.0015 mM
0.005
(5E,9E)-13,14-epoxy-6,10,14-trimethyl-1-methylthio-1,5,9-pentadecatriene
-
IC50: 0.005 mM
0.00005
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
-
IC50: 0.00005 mM
0.001
(5E,9E,13E)-17,18-epoxy-5,10,14,18-tetramethyl-1-methylthio-1,5,9,13-nonadecatetraene
-
IC50: 0.001 mM
0.06
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene, IC50: 0.06 mM
0.018
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
-
IC50: 0.018 mM
0.032
(5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-vinyl-2,5,9,13,17-tricosapentaene
-
IC50: 0.032 mM
0.02
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.02 mM
0.05
(5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.05 mM
0.06
(5Z,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-2,9,14,18,22-pentamethyl-5-(trimethylsilylethynyl)tricosa-2,5,9,13,17-pentaene, IC50: 0.06 mM
0.02
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.02 mM
0.05
(5Z,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene
-
+ (5E,9E,13E,17E)-21,22-epoxy-5-ethynyl-2,9,14,18,22-pentamethyltricosa-2,5,9,13,17-pentaene, IC50: 0.05 mM
0.003
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.003 mM, at a protein concentration of 3 mg/ml
0.0048
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.0048 mM, at a protein concentration of 5 mg/ml
0.005
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.005 mM, at a protein concentration of 2 mg/ml
0.005
(6E)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: 0.005 mM, at a protein concentration of 1 mg/ml
0.004
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.004 mM
0.005
(6E,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.005 mM
0.03
(6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
0.02
(6Z)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.02 mM, at a protein concentration of 5 mg/ml
0.1
(6Z)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.1 mM, at a protein concentration of 3 mg/ml
0.1
(6Z)-10-Aza-10,11-dihydrosqualene-2,3-epoxide
-
IC50: above 0.1 mM, at a protein concentration of 2 mg/ml
0.0022
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
-
IC50: 0.0022 mM
0.012
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-(2-methylthiovinyl)-2,6,10,14,18-tetracosapentaene
-
IC50: 0.012 mM
0.0004
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.0004 mM
0.001
(6Z,10E,14E,18E)-22,23-epoxy-2,10,15,19,23-pentamethyl-6-vinyl-2,6,10,14,18-tetracosapentaene
-
IC50: 0.001 mM
0.03
(6Z,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene
-
+ (6E,10E,14E,18E)-22,23-epoxy-6-ethynyl-2,10,15,19,23-pentamethyltetracosa-2,6,10,14,18-pentaene, IC50: 0.03 mM
0.000083
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
-
IC50: 83 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
0.000124
(Z)-3-[4-(4-bromobenzoyl)phenacylidene]quinuclidine
-
IC50: 124 nM, oral and selective inhibition of cholesterol biosynthesis derived from enzyme inhibition
0.000112
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
IC50: 112 nM
0.000398
1-(2-methyl-4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
76% inhibition at 0.001 mM, IC50: 398 nM
0.000082
1-(4-iodophenylsulfonyl)-4-(1-(4-pyridyl)piperidon-4-ylcarbonyl)piperazine
-
IC50: 82 nM
0.000037
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
IC50: 37 nM
0.000116
1-(4-pyrimidinyl)-4-(1-(4-bromophenylsulfonyl)piperazin-4-ylcarbonyl)piperidine
-
complete inhibition at 0.001 mM, IC50: 116 nM
0.00002
1-[4-(trifluoromethoxy)phenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmeth yl]-piperazine
-
-
0.000316
1-[4-chlorobenzyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(1-methyl-pyrazol-4-yl)phenylmethyl]-piperazine
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenylmethyl]-piperazine
-
-
0.00004
1-[4-chlorophenylcarbonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
-
-
0.000032
1-[4-chlorophenylcarbonyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-1-yl)phenylmethyl]-piperazine
-
-
0.0002
1-[4-chlorophenylcarbonyl]-4-[4-(pyrazol-3-yl)phenylmethyl]-piperazine
-
-
0.000003
1-[4-chlorophenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
0.0005
1-[4-chlorophenylsulfonyl]-4-[3-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
0.000006
1-[4-chlorophenylsulfonyl]-4-[4-(4-methylpiperazin-1-yl)phenylmethyl]-piperazine
-
-
0.000032
1-[4-chlorophenylsulfonyl]-4-[4-(dimethylaminomethyl)phenylmethyl]-piperazine
-
-
0.000013
1-[4-chlorophenylsulfonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
0.002511
1-[4-methoxyphenylcarbonyl]-4-[4-(pyridin-4-yl)phenylmethyl]-piperazine
-
-
0.0002
1-[4-trifluoroacetyl]-4-[4-(imidazol-1-yl)phenylmethyl]-piperazine
-
-
0.1
18,19-dihydro-29-methylidene-2,3-oxidosqualene
-
IC50: 0.1 mM
0.015
18-heptanor-2,3-oxidosqualene
-
IC50: 0.015 mM
0.07
18-heptanor-2,3-oxidosqualene
-
IC50: 0.07 mM
0.0015
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.0015 mM
0.0075
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.0075 mM, protein concentration of 5 mg/ml
0.022
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.022 mM, protein concentration of 3 mg/ml
0.035
19-aza-18,19,22,23-tetrahydrosqualene-2,3-epoxide
-
IC50: 0.035 mM, at a protein concentration of 2 mg/ml
0.15
2-Aza-2,3-dihydrosqualene
-
IC50: 2.3 mM, pig microsomes. IC50: 0.15 mM, solubilized enzyme
6.5
2-Aza-2,3-dihydrosqualene
-
IC50: 6.5 mM
7.5
2-Aza-2,3-dihydrosqualene
-
IC50: 7.5 mM
10
2-Aza-2,3-dihydrosqualene
-
IC50: 10 mM
3.3
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 7 mM, pig microsomes. IC50: 3.3 mM, solubilized enzyme
3.7
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 3.7 mM
16
2-Aza-2,3-dihydrosqualene N-oxide
-
IC50: 16 mM
0.0025
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
-
IC50: 0.0025 mM
0.006
2-[(4E,8E)-12,13-epoxy-5,9,13-trimethyl-4,8-tetradecadienylidene]-1,3-dithiane
-
IC50: 0.006 mM
0.0035
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
-
IC50: 0.0035 mM
0.012
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-benzodithiole
-
IC50: 0.012 mM
0.00017
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
-
IC50: 0.00017 mM
0.00035
2-[(4E,8E,12E)-16,17-epoxy-4,9,13,17-tetramethyl-4,8,12-octadecatrienylidene]-1,3-dithiane
-
IC50: 0.00035 mM
0.035
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
-
IC50: 0.035 mM
0.1
2-[(4E,8E,12E,16E)-20,21-epoxy-4,8,13,17,21-pentamethyl-4,8,12,16-docosatetraenylidene]-1,3-dithiane
-
IC50: 0.1 mM
0.18
27-norsqualene
-
pH 7.4, 37C, liver microsomes
0.076
29-norsqualene
-
pH 7.4, 37C, liver microsomes
0.0015
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
-
IC50: 0.0015 mM
0.0035
3-(3,7-Dimethyl-octadeca-3,7,11,15-tetraenyl)-2,2-dimethyl-oxirane
-
IC50: 0.0035 mM
0.00028
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 280 nM
0.00075
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 750 nM
0.016
3-(biphenyl-4-yloxy)-N,N-dimethylpropan-1-amine
-
IC50: 0.016 mM
0.00016
3-[(4-chlorobenzoyl)-4-phenoxy]quinuclidine
-
IC50: 160 nM
0.0000041
allyl-6-[4-(4-bromophenyl)-1H-benzo[d][1,2]oxazin-7-yloxy]hexylmethylamine
-
IC50: 4.1 nM
0.0000079
allyl[6-[1-(4-bromophenyl)-3,4-dihydroisoquinolin-6-yloxy]hexyl]methylamine
-
IC50: 7.9 nM
0.0000035
allyl[6-[1-(4-bromophenyl)isoquinolin-6-yloxy]hexyl]methylamine
-
IC50: 3.5 nM
0.0000196
allyl[6-[3-(4-bromophenyl)-1-methyl-1H-indazol-6-yloxy]hexyl]methylamine
-
IC50: 19.6 nM
0.0000056
allyl[6-[3-(4-bromophenyl)benzo[b]thiophen-6-yloxy]hexyl]methylamine
-
IC50: 5.6 nM
0.0000029
allyl[6-[3-(4-bromophenyl)benzo[d]isothiazol-6-yloxy]hexyl]methylamine
-
IC50: 2.9 nM
0.0000114
allyl[6-[4-(4-bromophenyl)-2H-chromen-7-yloxy]hexyl]methylamine
-
IC50: 11.4 nM
0.0000123
allyl[6-[4-(4-bromophenyl)quinazolin-7-yloxy]hexyl]methylamine
-
IC50: 12.3 nM
0.0000078
allyl[6-[4-(6-bromo-1,1-dioxobenzo[d]isothiazol-3-yl)phenoxy]hexyl]methylamine
-
IC50: 7.8 nM
0.055
azasqualene alcohol N-oxide
-
IC50: 0.055 mM, at a protein concentration of 3 mg/ml
0.055
azasqualene alcohol N-oxide
-
IC50: 0.055 mM, at a protein concentration of 2 mg/ml
0.00000585
BIBB 515
-
-
-
1.5
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
-
IC50: 1.5 mM
14
diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-aminoxide
-
IC50: 14 mM
3.2
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 3.2 mM
12.5
Diethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 12.5 mM
0.005
N,N-dimethyl-N-(4-methylenebenzophenonyl)amine
-
IC50: 0.005 mM
0.059
N-(2-methylenebenzophenonyl)pyridinium
-
IC50: 0.059 mM
0.016
N-(3-methylenebenzophenonyl)pyridinium bromide
-
IC50: 0.016 mM
0.00079
N-(4-methylenebenzophenonyl)pyridinium bromide
-
IC50: 0.00079 mM
0.0002
N-[2-(4-(3-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
-
-
0.000063
N-[2-(4-(4-((pyrrolidin-1-yl)methyl)phenyl)phenyl)ethyl]-4-chlorobenzenesulfonamide
-
-
0.000028
N-[2-(4-(4-dimethylaminomethylphenyl)phenyl)ethyl]-4-cyanobenzenesulfonamide
-
-
0.0025
N-[3-(1,1'-biphenyl-4-yloxy)propyl]-N,N-dimethylamine
-
IC50: 2500 nM
0.0000065
Ro 48-8071
-
IC50: 6.5 nM for the human liver enzyme
0.000008
Ro 48-8071
-
IC50: 8.0 nM for the recombinant enzyme
0.000022
Ro48-8071
-
IC50: 22 nM
5.1
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 5.1 mM
13.3
Trimethyl-(4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-pentaenyl)-ammonium
-
IC50: 13.3 mM
0.000022
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 22 nM
0.000092
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 92 nM
0.0004
[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl](4-chlorophenyl)methanone
-
IC50: 400 nM
0.000161
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 161 nM
0.000228
[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methanone
-
IC50: 228 nM
0.0000063
[4-[6-(allylmethylamino)hexyloxy]-2-hydroxyphenyl](4-bromophenyl)methanone
-
IC50: 6.3 nM
0.0000046
[4-[6-(allylmethylamino)hexyloxy]-2-methoxyphenyl](4-bromophenyl)methanone
-
IC50: 4.6 nM
0.0000041
[4-[6-(allylmethylamino)hexyloxy]-2-methylaminophenyl](4-bromophenyl)methanone
-
IC50: 4.1 nM
0.0000062
[4-[6-(allylmethylamino)hexyloxy]-2-methylsulfanylphenyl](4-bromophenyl)methanone
-
IC50: 6.2 nM
0.0000054
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-bromophenol)methanone
-
IC50: 5.4 nM
0.0000019
[4-[6-(allylmethylamino)hexyloxy]phenyl](4-nitrophenyl)methanone
-
IC50: 1.9 nM
0.0000067
[4-[6-(allylmethylamino)hexyloxy]phenyl]-(4-fluorophenyl)methanone
-
IC50: 6.7 nM
0.0000225
[4-[6-(allylmethylamino)hexyloxy]phenyl]phenylmethanone
-
IC50: 22.5 nM
0.000049
[5-(4-(4-chloro-benzoyl)-3-fluoro-phenoxy)-pentyl]-methyl-propyl-ammonium fumarate
-
IC50: 49 nM
0.0000087
[6-[6-(allylmethylamino)hexyloxy]pyridin-3-yl](4-bromophenyl)methanone
-
IC50: 8.7 nM
0.0000353
[6-[6-(cyclopropylmethylamino)hexyloxy]phenyl](4-bromophenyl)methanone
-
IC50: 35.3 nM
0.00009
{4-[4-(4,5-Dihydro-oxazol-2-yl)-benzylidene]-piperidin-1-yl}-(4-trifluoromethyl-phenyl)-methanone
-
IC50: 90 nM, complete inhibition at 0.001 nM
0.0000043
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 4.3 nM
0.0000046
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 4.6 nM
0.000071
{4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-chloro-phenyl)-methanone
-
IC50: 71 nM
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
0.0000015
P38604
mutant C457/E526A at 25C; mutant C457/E526C at 25C
0.0000025
P38604
mutant C457/E526C at 35C
0.0000048
P38604
mutant C457/E526A at 35C
0.0000063
P38604
mutant C457 at 25C
0.0000087
P38604
mutant C457/E526D at 25C
0.0000097
P38604
mutant C457/E526Q at 25C
0.0000113
P38604
mutant C457/E525C at 25C
0.0000128
P38604
mutant C457/E526D at 35C
0.0000172
P38604
wild-type, at 25C
0.0000192
P38604
mutant C457/E526Q at 35C
0.000021
P38604
mutant C457/E525C at 35C
0.0000213
P38604
mutant C457 at 35C
0.0000292
P38604
wild-type, at 35C
0.0000429
P48450
cataractous Shumiya cataract rat
0.000046
P48450
normal Shumiya cataract rat
0.0043
-
-
1.747
-
-
additional information
-
-
additional information
-
-
additional information
-
-
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
7.4
-
-
7.4
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
6 - 9
-
pH 6.0: about 20% of maximal activity, pH 7.0: about 90% of maximal activity, pH 9.0: about 50% of maximal activity
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
37
-
assay at
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
25 - 50
-
optimal activity between 25C and 50C with a maximum at 37C
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
83000
-
SDS-PAGE
703517
86000
-
equilibrium sedimentation
649634
90000
-
gel filtration
3590
140000
-
non-denaturing PAGE
649491
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
?
-
x * 80000, SDS-PAGE
?
-
x * 90000, SDS-PAGE
?
-
x * 26000, SDS-PAGE
?
-
x * 65000, SDS-PAGE
?
-
x * 83400, calculation from nucleotide sequence
?
-
x * 83000, calculation from nucleotide sequence
?
-
x * 72000, SDS-PAGE, x * 76000, calculated
?
-
x * 90000, SDS-PAGE, x * 94000, calculated for thioredoxin-enzyme fusion protein
dimer
-
2 * 75000, SDS-PAGE
dimer
-
2 * 70000, SDS-PAGE
monomer
-
1 * 80000, SDS-PAGE
monomer
-
crystal analysis
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
-
the protein is neither glycosylated nor modified post-translationally
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
hanging-drop vapor-diffusion method
-
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
mutants C457D/E526C and C457D/E526A are not stable at 35C
P38604
rapid loss of activity on freezing and thawing
-
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-20C or -80C, phosphate buffer, in presence of Triton and DTT, stable for up to 6 months
-
-80C, 10% glycerol, stable for at least 1 year
-
0C, 2 weeks, stable
-
-70C, stable for at least several months
-
0C, stable
-
4C, in presence of sodium azide, 5% loss of activity after 40 days
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
His-Bind resin column chromatography and ammonium sulfate precipitation
-
liver microsome preparation
-
partial
-
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
expression in Saccharomyces cerevisiae
-
expressed in Saccharomyces cerevisiae GIL77 cells
-
expression in Saccharomyces cerevisiae
-
expressed in Saccharomyces cerevisiae strain erg7
D7NJ68
-
P48449
expression in Pichia pastoris
-
expression in Saccharomyces cerevisiae
-
expression in Escherichia coli
Q603D4
expressed in an ERG7-null mutant of Saccharomyces cerevisiae
-
expression in Saccharomyces cerevisiae
-
expression in Saccharomyces cerevisiae
-
expression in yeast strains RXY6 and SMY8
-
mutants are expressed in Saccharomyces cerevisiae strain TKW14
-
expression in Saccharomyces cerevisiae
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
methyl jasmonate up-regulates lanosterol synthase mRNA expression 3.75 and 3.67fold after 2 days when cultivated on 0.01 and 0.05 mM, respectively
D7NJ68
methyl jasmonate up-regulates lanosterol synthase mRNA expression 3.75 and 3.67fold after 2 days when cultivated on 0.01 and 0.05 mM, respectively
Ganoderma lucidum HG
-
-
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
H232S
-
site-directed mutagenesis, mutant energy profile compared to the wild-type enzyme
H232T
-
site-directed mutagenesis, mutant energy profile compared to the wild-type enzyme
N478H/V482I
-
change of amino acids crucial for specificity to the cycloartenol synthase type. Mutant produces 4% lanosterol, 83% parkeol, and 13% cycloartenol from substrate (S)-2,3-epoxysqualene
D139N
P48450
reduced activity
D139N/G189A/Q481R
P48450
induces cataracts in rats, produces only 39% of the lanosterol produced by wild-type
H469-C472del
P48450
deletion allele, inactive
C457D
P38604
less active than the wild-type
C457D/A525C
P38604
similar activity as the wild-type
C457D/E526A
P38604
decrease in enzyme functionality
C457D/E526C
P38604
very sensitive to the thiol-reacting agent dodecylmaleimide, specific activity and thermal stability are severely reduced
C457D/E526D
P38604
no effect on catalytic avtivity
C457D/E526Q
P38604
no effect on catalytic avtivity
C457G
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
C457G/T509G
-
site-directed mutagenesis, the mutations disrupt the pre-existing H-bond to the protonating Asp456 and the intrinsic His234-Tyr510 H-bond network, respectively, and generates achilleol A as the major product
C703D
-
site-directed mutagenesis, the mutant shows unaltered product spectrum compared to the wild-type enzyme
C703G
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
C703H
-
site-directed mutagenesis, the mutant generates an unusual truncated bicyclic rearranged intermediate, (8R,9R,10R)-polypoda-5,13E,17E,21-tetraen-3beta-ol, related to iridal-skeleton triterpenoid. Numerous oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are also isolated from the mutant
C703I
-
site-directed mutagenesis, the mutant generates an unusual truncated bicyclic rearranged intermediate, (8R,9R,10R)-polypoda-5,13E,17E,21-tetraen-3beta-ol, related to iridal-skeleton triterpenoid. Numerous oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are also isolated from the mutant
C703N
-
site-directed mutagenesis, the mutant shows unaltered product spectrum compared to the wild-type enzyme
C703S
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
C703T
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
C703V
-
site-directed mutagenesis, the mutant shows altered product spectrum compared to the wild-type enzyme, but not as diverse as mutants C703I and C703H
F445C
-
produces 10% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 69% lanosterol, 13% parkeol, 8% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445D
-
produces 21% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 63% lanosterol, 11% parkeol, 5% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445M
-
produces 7% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 65% lanosterol, 18% parkeol, 10% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445N
-
produces 10% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 63% lanosterol, 9% parkeol, 18% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F445T
-
produces 49% (13alphaH)-iso-malabarica-14(16)-17E,21-trien-3beta-ol, 46% lanosterol, 5% 9beta-lanosta-7,24-dien-3beta-ol from substrate (S)-2,3-epoxysqualene
F699A/C703I
-
site-directed mutagenesis, inactive mutant
F699C
-
inactive
F699C
-
the mutant is inactive
F699C/I705F
-
the mutant is inactive
F699H
-
the mutant produces lanosterol (13%), protosta-13(17)-dien-3beta-ol (70%), and (17Z)-protosta-17(20),24-dien-3beta-ol (17%)
F699I
-
the mutant produces lanosterol (100%) as the wild type enzyme
F699L
-
the mutant produces lanosterol (100%) as the wild type enzyme
F699M
-
the mutant produces lanosterol (13%), (17Z)-protosta-17(20),24-dien-3beta-ol (46%), protosta-13(17)-dien-3beta-ol (70%), malabarica-14E,17E,21-trien-3beta-ol (7%), 17alpha-protosta-20,24-dien-3beta-ol (1%), (17Z)-protosta-17(20),24-dien-3beta-ol (10%), (13alphaH)-isomalabarica-14E,17E,21-dien-3 beta-ol (17%), and (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol (18%)
F699M
-
the mutant produces 1% lanosterol, 17% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 18% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 46% protosta-13(17),24-dien-3beta-ol, 1% 17alpha-protosta-20,24-dien-3beta-ol, 10% protosta-17(20),24-dien-3beta-ol and 7% malabarica-14E,17E,21-trien-3beta-ol from (3S)-2,3-oxidosqualene
F699M/C703I
-
site-directed mutagenesis, inactive mutant
F699M/I705F
-
the mutant produces 53% lanosterol, 17% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 12% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 15% protosta-13(17),24-dien-3beta-ol, and 3% 17alpha-protosta-20(22),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
F699N
-
nonviable mutant, does not produce lanosterol, but protosta-13(17)-dien-3beta-ol (55%), malabarica-14E,17E,21-trien-3beta-ol (5%), 17alpha-protosta-20,24-dien-3beta-ol (24%), and (17Z)-protosta-17(20),24-dien-3beta-ol (16%)
F699P
-
the mutant produces lanosterol (100%) as the wild type enzyme
F699Q
-
inactive
F699S
-
inactive
F699T
-
the mutant produces novel protosta-13(17),24-dien-3beta-ol as the sole truncated rearrangement product from (S)-2,3-oxidosqualene
F699T
-
the mutant produces protosta-13(17),24-dien-3beta-ol from (S)-2,3-oxidosqualene
F699T
-
the mutant produces lanosterol (less than 0.2%) and protosta-13(17)-dien-3beta-ol (above 99.8%)
F699T
-
the mutant produces less than 0.2% lanosterol and more than 99.8% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
F699T/C703I
-
site-directed mutagenesis, different oxidosqualene-cyclized truncated intermediates, including tricyclic, unrearranged tetracyclic with 17alpha/beta exocyclic hydrocarbon side chain, rearranged tetracyclic, and chair-chair-chair tricyclic intermediates, are isolated from the mutant
F699T/I105F
-
the mutant produces 36% lanosterol, 45% protosta-13(17),24-dien-3beta-ol, 7% 17alpha-protosta-20,24-dien-3beta-ol, and 12% 17alpha-protosta-20(22),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
F699X
-
TKW14[pERG7F699X] site-saturated mutants allow for ergosterol-independent growth, with the exception of Leu, Ile, His, Met, Pro, and Thr substitutions
F699Y
-
inactive
H234A
-
products are 17% protosta-12,24-dien-3beta-ol, 13% protosta-20,24-dien-3beta-ol, 30% lanosterol, 40% parkeol
H234C
-
products are 7% protosta-12,24-dien-3beta-ol, 4% protosta-20,24-dien-3beta-ol, 67% lanosterol, 22% parkeol
H234D
-
products are 58% iso-malabarica-14(16),17,21-trien-3beta-ol, 30% lanosterol, 12% parkeol
H234E
-
products are 49% lanosterol, 51% parkeol
H234F
-
products are 66% achilleol A, 14% lanosterol, 20% parkeol
H234G
-
products are 29% protosta-12,24-dien-3beta-ol, 7% protosta-20,24-dien-3beta-ol, 17% lanosterol, 47% parkeol
H234I
-
products are 70% lanosterol, 30% parkeol
H234K
-
no catalytic activity
H234L
-
products are 39% lanosterol, 31% parkeol, 30% iso-malabarica-14(16),17,21-trien-3beta-ol
H234M
-
products are 17% achilleol A, 10% iso-malabarica-14(16),17,21-trien-3beta-ol, 30% lanosterol, 40% parkeol
H234N
-
products are 23% protosta-12,24-dien-3beta-ol, 14% protosta-20,24-dien-3beta-ol, 27% lanosterol, 10% parkeol, 26% iso-malabarica-14(16),17,21-trien-3beta-ol
H234P
-
products are 64% lanosterol, 36% parkeol
H234Q
-
product is 100% lanosterol, like wild-type
H234R
-
no catalytic activity
H234S
-
product is 100% protosta-12,24-dien-3beta-ol
H234T
-
product is 100% parkeol
H234V
-
products are 42% lanosterol, 58% parkeol
H234W
-
product is 100% parkeol
H234W/Y510V
-
the mutant produces achilleol A, (13H)-isomalabarica-14(26),17E,21-trien-3beta-ol, and lanosterol at a 2:8:90 ratio from (S)-2,3-oxidosqualene
H234W/Y510W
-
mutant produces achilleol A from (S)-2,3-oxidosqualene
H234W/Y510W
-
site-directed mutagenesis, the double mutation alters the ERG7 function to achilleol A synthase activity and generates achilleol A as the sole product
H234Y
-
products are 14% achilleol A, 26% protosta-12,24-dien-3beta-ol, 51% lanosterol, 9% parkeol
H234Y/Y510A
-
the mutant produces lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
I705A
-
the mutant produces 78% lanosterol, 13% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 8% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 0.3% protosta-13(17),24-dien-3beta-ol, and 0.7% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705C
-
the mutant produces 72% lanosterol, 16% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 11.7% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 0.3% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705D
-
the mutant produces 37% lanosterol, 32% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 30% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 1% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705F
-
the mutant produces 25% lanosterol, 21(13alphaH)-isomalabarica-14(26),17E,21-trien-3beta-ol, 6% 17alpha-protosta-20,24-dien-3beta-ol, 42% 17alpha-protosta-20(22),24-dien-3beta-ol from, and 6% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705G
-
the mutant produces 35% lanosterol, 23% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 34% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 6% protosta-13(17),24-dien-3beta-ol, 1% 17alpha-protosta-20(22),24-dien-3beta-ol and 1% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705K
-
the mutant produces 12% lanosterol, 26.5% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 53.1% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 7.6% protosta-13(17),24-dien-3beta-ol, and 0.8% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705L
-
the mutant produces 100% lanosterol from (3S)-2,3-oxidosqualene (wild-type activity)
I705M
-
the mutant produces 88% lanosterol, 6% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, and 6% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705N
-
the mutant produces 19% lanosterol, 41% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 37% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 3% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705P
-
the mutant produces 81.9% lanosterol, 0.1% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 15% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 3% protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705Q
-
the mutant produces 25% lanosterol, 39% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 31% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 5% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705S
-
the mutant produces 12% lanosterol, 42% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 44% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, 1% protosta-13(17),24-dien-3beta-ol, and 1%protosta-16,24-dien-3beta-ol from (3S)-2,3-oxidosqualene
I705T
-
the mutant produces 22% lanosterol, 36% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, 41% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol, and 1% protosta-13(17),24-dien-3beta-ol from (3S)-2,3-oxidosqualene
Q450H
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme produng exclusively achilleol A as product
Q450H/V454I
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing lanosterol, (13alphaH)-isomalabarica-14(26),17E,21-trien-3beta-ol, and protosta-16,24-dien-3beta-ol
T384Y
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing lanosterol, parkeol, and 9beta-lanosta-7,24-dien-3beta-ol
T384Y/Q450H
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing mainly parkeol and very low amounts of 9beta-lanosta-7,24-dien-3beta-ol and lanosterol
T384Y/Q450H/V454I
-
site-directed mutagenesis, the mutant produces exclusively reaction intermediate parkeol but not lanosterol as the sole end product
T384Y/V454I
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing mainly parkeol and lower amounts of 9beta-lanosta-7,24-dien-3beta-ol and lanosterol
T509G
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
V454A
-
results in the production of an additional truncated monocyclic achilleol A
V454G
-
results in the production of an additional truncated monocyclic achilleol A
V454I
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme producing mainly lanosterol and a low amount of (13alphaH)-isomalabarica-14(26),17E,21-trien-3beta-ol
W232A
-
products are 18.1% protosta-12,24-dien-3beta-ol, 47.1% lanosterol, 34.8% parkeol
W232C
-
products are 18% protosta-12,24-dien-3beta-ol, 31.8% lanosterol, 50.2% parkeol
W232D
-
products are 7.9% protosta-12,24-dien-3beta-ol, 84.8% lanosterol, 7.3% parkeol
W232E
-
products are 14% protosta-12,24-dien-3beta-ol, 49.2% lanosterol, 36.8% parkeol
W232F
-
products are 8.4% protosta-12,24-dien-3beta-ol, 74.4% lanosterol, 17,2% parkeol
W232G
-
products are 8.4% protosta-12,24-dien-3beta-ol, 74.4% lanosterol, 17.2% parkeol
W232H
-
products are 27.8% protosta-12,24-dien-3beta-ol, 35% lanosterol, 37.2% parkeol
W232I
-
products are 23.5% protosta-12,24-dien-3beta-ol, 33% lanosterol, 43.5% parkeol
W232K
-
no catalytic activity
W232L
-
products are 14.5% protosta-12,24-dien-3beta-ol, 27.8% lanosterol, 57.7% parkeol
W232M
-
products are 10.9% protosta-12,24-dien-3beta-ol, 40.6% lanosterol, 48.5% parkeol
W232N
-
products are 10.7% protosta-12,24-dien-3beta-ol, 59.5% lanosterol, 29.8% parkeol
W232P
-
products are 4.4% protosta-12,24-dien-3beta-ol, 82.9% lanosterol, 12.7% parkeol
W232Q
-
products are 24.6% protosta-12,24-dien-3beta-ol, 32.1% lanosterol, 43.3% parkeol
W232R
-
no catalytic activity
W232S
-
products are 10.7% protosta-12,24-dien-3beta-ol, 59% lanosterol, 30.3% parkeol
W232T
-
products are 14.3% protosta-12,24-dien-3beta-ol, 61.7% lanosterol, 24% parkeol
W232V
-
products are 19.3% protosta-12,24-dien-3beta-ol, 34% lanosterol, 46.7% parkeol
W232Y
-
products are 4.2% protosta-12,24-dien-3beta-ol, 94.2% lanosterol, 1.6% parkeol
W587F
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
W587Y
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510A
-
produces lanosterol, parkeol and achilleol A in a 39:34:27 ratio
Y510A
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510C
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510F
-
produces lanosterol and isomalabaricatrienol in a 95:5 ratio in strain RXY6, while in strain SMY8, the ratio is 10:90
Y510H
-
incomplete cyclization, produces achilleol (45%), lanosterol (42%), parkeol (9%), and isomalabaricatrienol (4%)
Y510H
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510K
-
inactive
Y510K
-
fails to maintain cell viability in the absence of ergosterol, in the presence of ergosterol the mutant produces achilleol A and camelliol C in a ratio of 86:14
Y510K
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510L
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510S
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y510W
-
inactive
Y510W
-
fails to maintain cell viability in the absence of ergosterol, in the presence of ergosterol the mutant produces achilleol A and camelliol C in a ratio of 96:4
Y510W
-
site-directed mutagenesis, the mutant shows an altered product profile compared to the wild-type enzyme, overview
Y707A
-
the mutant produces 18.9% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 56.9% lanosterol, 19.9% 9beta-lanosta-7,24-dien-3beta-ol, and 4.3% parkeol from (S)-2,3-oxidosqualene
Y707C
-
the mutant produces 6% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 47.1% lanosterol, 42.6% 9beta-lanosta-7,24-dien-3beta-ol, and 4.3% parkeol from (S)-2,3-oxidosqualene
Y707D
-
the mutant produces 21.8% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 67.3% lanosterol, 7.6% 9beta-lanosta-7,24-dien-3beta-ol, and 3.3% parkeol from (S)-2,3-oxidosqualene
Y707E
-
the mutant produces 12.3% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 70.8% lanosterol, 10.5% 9beta-lanosta-7,24-dien-3beta-ol, and 6.4% parkeol from (S)-2,3-oxidosqualene
Y707F
-
the mutant produces 89.2% lanosterol, 3.1% parkeol, and 7.7% 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
Y707G
-
the mutant produces 28.3% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 48.2% lanosterol, 16.3% 9beta-lanosta-7,24-dien-3beta-ol, and 7.2% parkeol from (S)-2,3-oxidosqualene
Y707H
-
the mutant produces 83.6% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 4.7% lanosterol, 6.2% 9beta-lanosta-7,24-dien-3beta-ol, and 5.5% parkeol from (S)-2,3-oxidosqualene
Y707I
-
the mutant produces 87.9% lanosterol and 12.1% 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
Y707K
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707L
-
the mutant produces 85.3% lanosterol and 14.7% 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
Y707M
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707N
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707P
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707Q
-
the mutant produces 82% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 4.3% lanosterol, and 13.7% parkeol from (S)-2,3-oxidosqualene
Y707R
-
inactive
Y707S
-
the mutant produces 21.3% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 42.9% lanosterol, 20.5% 9beta-lanosta-7,24-dien-3beta-ol, and 15.3% parkeol from (S)-2,3-oxidosqualene
Y707T
-
the mutant produces 9.8% (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, 65.1% lanosterol, 13.5% 9beta-lanosta-7,24-dien-3beta-ol, and 11.6% parkeol from (S)-2,3-oxidosqualene
Y707V
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707W
-
the mutant produces 100% lanosterol from (S)-2,3-oxidosqualene (wild type reaction)
Y707X
-
the mutant produces (9R,10S)-polypoda-8(26),13E,17E,21-tetraen-3beta-ol, in addition to lanosterol, parkeol, and 9beta-lanosta-7,24-dien-3beta-ol from (S)-2,3-oxidosqualene
C457D
Saccharomyces cerevisiae SMY8
-
less active than the wild-type
-
C457D/E526A
Saccharomyces cerevisiae SMY8
-
decrease in enzyme functionality
-
C457D/E526C
Saccharomyces cerevisiae SMY8
-
very sensitive to the thiol-reacting agent dodecylmaleimide, specific activity and thermal stability are severely reduced
-
C457D/E526D
Saccharomyces cerevisiae SMY8
-
no effect on catalytic avtivity
-
C457D/E526Q
Saccharomyces cerevisiae SMY8
-
no effect on catalytic avtivity
-
F699I
Saccharomyces cerevisiae TKW14
-
the mutant produces lanosterol (100%) as the wild type enzyme
-
F699L
Saccharomyces cerevisiae TKW14
-
the mutant produces lanosterol (100%) as the wild type enzyme
-
F699N
Saccharomyces cerevisiae TKW14
-
nonviable mutant, does not produce lanosterol, but protosta-13(17)-dien-3beta-ol (55%), malabarica-14E,17E,21-trien-3beta-ol (5%), 17alpha-protosta-20,24-dien-3beta-ol (24%), and (17Z)-protosta-17(20),24-dien-3beta-ol (16%)
-
F699T
Saccharomyces cerevisiae TKW14
-
the mutant produces lanosterol (less than 0.2%) and protosta-13(17)-dien-3beta-ol (above 99.8%)
-
F699X
Saccharomyces cerevisiae TKW14
-
TKW14[pERG7F699X] site-saturated mutants allow for ergosterol-independent growth, with the exception of Leu, Ile, His, Met, Pro, and Thr substitutions
-
additional information
Q1G1A4
no visible morphological phenotypes are observed in enzyme disruption mutant and no differences in sterol profiles between the wild type and mutant are detected. Enzyme gene complements enzyme-deficient yeast strain
additional information
-
an oxidosqualene:protostadienol cyclase mutant in which the C-terminal residues 702APPGGMR708 are replaced with 702NKSCAIS708 efficiently produces a 1:1 mixture of lanosterol and parkeol
I705V
-
the mutant produces 75% lanosterol, 10% (13alphaH)-isomalabarica-14E,17E,21-dien-3beta-ol, and 15% (13alphaH)-isomalabarica-14Z,17E,21-dien-3beta-ol from (3S)-2,3-oxidosqualene
additional information
-
only polar side-chain group substitutions of F445 genetically complement yeast viability and produce spatially related product diversity
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
drug development
-
the enzyme represents a novel target for treatment of hypercholesterolemia and atherosclerosis
drug development
P48449
the enzyme represents a target for the discovery of novel anticholesteraemic drugs
medicine
-
target for the development of new hypocjolesterolemic drugs
medicine
-
S23515 can exert hypolipidemic effects in addition to its hypotensive activities
nutrition
-
since lanosterol synthase is located in the middle stage of the biosynthetic pathway of cholesterol in mammals, it may be important to know the acyl composition of digalactosyl diacylglycerol in vegetables for evaluating the efficacy of them against hypercholesterolemia
medicine
-
S23515 can exert hypolipidemic effects in addition to its hypotensive activities
drug development
-
results identify a particularly promising new family of OSC inhibitors, for the development of novel antiparasitic agents
medicine
-
S23515 can exert hypolipidemic effects in addition to its hypotensive activities
medicine
P48450
since the Shumiya cataract rat model represents a new example of hereditary cholesterol deficiency-associated cataracts, it should be useful in the development of therapeutic and/or preventive measures for cataracts
drug development
-
results identify a particularly promising new family of OSC inhibitors, for the development of novel antiparasitic agents
synthesis
-
engineering ERG7 for producing biological active agents is promising
drug development
-
the enzyme represents a novel target for treatment of hypercholesterolemia and atherosclerosis
drug development
-
results identify a particularly promising new family of OSC inhibitors, for the development of novel antiparasitic agents